Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN FRANCISCO, JUNE 02, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO SIX NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 176,150 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF JUNE 1, 2026. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

OLEMA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

STUDY TO EVALUATE OP-3136, OLEMA'S NOVEL KAT6 INHIBITOR, IN COMBINATION WITH DAROLUTAMIDE IN APPROXIMATELY 36 PATIENTS; EXPECTED TO INITIATE IN H2 2026 FIRST CLINICAL COLLABORATION FOR OP-3136; RESULTS TO INFORM COMBINATION STRATEGY IN METASTATIC PROSTATE CANCER SETTING SAN FRANCISCO, MAY 26, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND,TODAY ANNOUNCED A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BAYER AG (BAYER) TO EVALUATE OP-3136, OLEMA'S INVESTIGATIONAL LYSINE ACETYLTRANSFERASE 6 (KAT6) INHIBITOR, IN COMBINATION WITH NUBEQA (DAROLUTAMIDE), BAYER'S ANDROGEN RECEPTOR INHIBITOR, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). THE PHASE 1B/2 STUDY IS DESIGNED TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF OP-3136 IN COMBINATION WITH DAROLUTAMIDE IN APPROXIMATELY 36 PATIENTS WITH MCRPC.

OLEMA ONCOLOGY ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BAYER TO EVALUATE OP-3136 IN COMBINATION WITH NUBEQA (DAROLUTAMIDE) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

OP-3136 MONOTHERAPY WAS WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED AND NO DISCONTINUATIONS DUE TO TREATMENT-RELATED ADVERSE EVENTS OP-3136 SHOWS EVIDENCE OF ANTI-TUMOR ACTIVITY ACROSS MULTIPLE SOLID TUMOR TYPES DATA SUPPORT THE ONGOING PHASE 1 EVALUATION OF OP-3136 AS A MONOTHERAPY AND IN COMBINATION WITH FULVESTRANT AND PALAZESTRANT SAN FRANCISCO, MAY 21, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED PRELIMINARY CLINICAL DATA FROM THE PHASE 1 STUDY OF OP-3136, A POTENT LYSINE ACETYLTRANSFERASE 6 (KAT6) INHIBITOR. THE DATA WILL BE PRESENTED IN A POSTER PRESENTATION ON MAY 30, 2026 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING TAKING PLACE IN CHICAGO, ILLINOIS.

OLEMA ONCOLOGY ANNOUNCES ENCOURAGING INITIAL CLINICAL DATA FROM THE PHASE 1 STUDY OF OP-3136, A KAT6 INHIBITOR, AT 2026 ASCO ANNUAL MEETING

SAN FRANCISCO, MAY 19, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: TD COWEN 7 TH ANNUAL ONCOLOGY INNOVATION SUMMIT DATE AND TIME: MAY 26, 2026 AT 12:30 P.M. ETFORMAT: FIRESIDE CHATLOCATION: VIRTUAL JEFFERIES GLOBAL HEALTHCARE CONFERENCE DATE AND TIME: JUNE 3, 2026 AT 8:45 A.M.

OLEMA ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SAN FRANCISCO, MAY 04, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FIVE NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 154,700 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF MAY 1, 2026. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, APRIL 29, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THE APPOINTMENT OF PRAKASH RAMAN, PH.D., TO ITS BOARD OF DIRECTORS.

OLEMA ONCOLOGY APPOINTS PRAKASH RAMAN, PH.D., TO BOARD OF DIRECTORS

SAN FRANCISCO, APRIL 21, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED IT WILL PRESENT INITIAL CLINICAL DATA FROM THE PHASE 1 STUDY OF OP-3136 IN A POSTER PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING TAKING PLACE MAY 29-JUNE 2 IN CHICAGO, ILLINOIS. THE COMPANY WILL ALSO PRESENT A TRIAL-IN-PROGRESS POSTER FOR THE PHASE 3 OPERA-02 TRIAL.

OLEMA ONCOLOGY TO PRESENT INITIAL CLINICAL DATA FOR OP-3136 AT THE 2026 ASCO ANNUAL MEETING

SAN FRANCISCO, APRIL 02, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 188,500 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF APRIL 1, 2026. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ON-TRACK TO REPORT TOP-LINE DATA IN THE FALL OF 2026 FROM THE PIVOTAL PHASE 3 OPERA-01 TRIAL OF PALAZESTRANT AS A MONOTHERAPY IN PATIENTS WITH 2/3L ER+/HER2- METASTATIC BREAST CANCER ADVANCED ENROLLMENT IN THE OPERA-02 PIVOTAL PHASE 3 TRIAL OF PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN PATIENTS WITH FRONTLINE ER+/HER2- METASTATIC BREAST CANCER INITIATED THE PHASE 1B/2 STUDY OF PALAZESTRANT IN COMBINATION WITH PFIZER'S NOVEL CDK4 INHIBITOR, ATIRMOCICLIB, IN PATIENTS WITH ER+/HER2- METASTATIC BREAST CANCER CONTINUED ENROLLMENT IN THE PHASE 1 CLINICAL STUDY OF OP-3136 IN BREAST CANCER AND OTHER SOLID TUMORS, WITH INITIAL CLINICAL DATA EXPECTED IN Q2 2026 GENERATED $218.5 MILLION IN GROSS PROCEEDS FROM A FOLLOW-ON PUBLIC OFFERING, FURTHER STRENGTHENING THE COMPANY'S BALANCE SHEET; ENDED 2025 WITH $505.4 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TRANSFORMATION INTO A FULLY-INTEGRATED ONCOLOGY COMPANY UNDERWAY IN PREPARATION FOR THE COMPANY'S FIRST POTENTIAL COMMERCIAL LAUNCH IN LATE 2027 SAN FRANCISCO, MARCH 16, 2026 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. 2025 WAS A YEAR OF STRONG EXECUTION ACROSS THE BUSINESS AS WE ADVANCED PALAZESTRANT AS A DIFFERENTIATED ENDOCRINE THERAPY ACROSS MULTIPLE REGIMENS, HIGHLIGHTED BY CONTINUED ENROLLMENT AND STRONG INVESTIGATOR INTEREST IN OUR OPERA-01 AND OPERA-02 TRIALS, SAID SEAN P.

OLEMA ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL AND OPERATING RESULTS

LOS ANGELES--(BUSINESS WIRE)--OLEMA PHARMACEUTICALS, INC. INVESTIGATED ON BEHALF OF INVESTORS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  OLMA.

Olema Pharmaceuticals, Inc.

OLMA

Price

Financial Reports

No items found.

Press Releases

Olema Pharmaceuticals, Inc.

OLMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OLMA